Jillian A. Bristol

A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection

Jillian A. Bristol, Reza Djavadian, Emily R. Albright et al. · PLoS Pathogens · 2018 · 92 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication

Andrea Bilger, Julie Plowshay, Shidong Ma et al. · Oncotarget · 2017 · 77 citations · Full text

Life Sciences, Immunology, Oncology +10

Hsp90 Inhibitor 17-DMAG Decreases Expression of Conserved Herpesvirus Protein Kinases and Reduces Virus Production in Epstein-Barr Virus-Infected Cells

Xiaoping Sun, Jillian A. Bristol, Satoko Iwahori et al. · Journal of Virology · 2013 · 50 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +8

Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential

Shi-Dong Ma, Ming‐Han Tsai, James C. Romero-Masters et al. · Journal of Virology · 2017 · 45 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection

James C. Romero-Masters, Shane M. Huebner, Makoto Ohashi et al. · PLoS Pathogens · 2020 · 42 citations · Full text

Life Sciences, Immunology, Molecular Biology +17